
Boehringer Ingelheim owns 3 brands in our database. Browse the complete portfolio of Boehringer Ingelheim subsidiaries and brands across various industries.
Company Type
private
Headquarters
Ingelheim am Rhein, Rhineland-Palatinate, Germany
Brand Portfolio
3 brands
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
Linagliptin DPP-4 inhibitor for type 2 diabetes, developed by Boehringer Ingelheim and co-marketed with Eli Lilly since its 2011 FDA approval.
Is Boehringer Ingelheim family-owned?
Yes. Boehringer Ingelheim has been continuously family-owned since 1885, held by the Boehringer, von Baumbach, and Engelhorn families. It has never listed shares publicly and states it intends to remain independent.
Is Boehringer Ingelheim publicly traded?
No. Boehringer Ingelheim is a private company with no stock listing. It is one of the world's largest privately held pharmaceutical companies and cannot be invested in through public markets.
When was Boehringer Ingelheim founded?
Boehringer Ingelheim was founded in 1885 in Ingelheim am Rhein, Germany, initially producing tartaric acid. It expanded into pharmaceuticals in the late 19th century and has operated for more than 140 years.
Who founded Boehringer Ingelheim?
Albert Boehringer founded the company in 1885. His descendants across the Boehringer, von Baumbach, and Engelhorn families still own it, now in the fifth and sixth generations.
What is Boehringer Ingelheim's market position?
Boehringer Ingelheim is a top-20 global pharmaceutical company with 2025 net sales of EUR 27.75 billion. Its largest product is Jardiance at EUR 8.8 billion, and it is also a top-tier animal health company led by the NexGard franchise.
Who leads Boehringer Ingelheim?
Shashank Deshpande has been chairman of the Board of Managing Directors since mid-2025, succeeding Hubertus von Baumbach, a fifth-generation family member who moved to the shareholders' committee. Deshpande previously led the Human Pharma division.
No competing brands found in the same categories. This could be because Boehringer Ingelheimoperates in unique market segments or we're still building our competitor database.
Boehringer Ingelheim maintains a diverse portfolio of 3 brands across multiple industries. This comprehensive brand portfolio demonstrates the company's market presence and strategic business units.
For consumers and researchers interested in corporate ownership structures, understanding which brands are owned by Boehringer Ingelheimprovides valuable insights into market dynamics, product relationships, and corporate strategy.